Search

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments
Patient registries: A catalyst for developing new therapies for rare diseases
Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Community Bulletin: MOMENTUM, Study SRP-5051-201, Update
Community Bulletin: COVID-19 Vaccination and Gene Therapy